Fish & Richardson Named #1 PTAB Law Firm of 2020 by Managing Intellectual Property
Fish & Richardson has been named the #1 law firm at the Patent Trial and Appeal Board (PTAB) for 2020 by Managing Intellectual Property (MIP) for the fifth consecutive year. Fish took the top spots for representing both petitioners and patent owners, with 104 and 94 appearances, respectively. Fish’s almost 200 appearances in 2020 are over 60% higher than the next firm on MIP’s 2020 rankings.
Fish Attorneys Author Law360 Article, “Lessons For 2021 From Fed. Circ. Post-Grant Review Cases”
Fish attorneys John Dragseth and Nitika Gupta Fiorella authored a Law360 Expert Analysis article discussing the post-grant appeals that drove a lot of the legal activity at the Federal Circuit this past year despite the pandemic and what the notable developments in 2020 may mean for 2021.
Dorothy Whelan Interviewed by Bloomberg Law: “Looming Judge Fight Threatens Generics’ Favored Patent Forum”
Dorothy Whelan, co-chair of Fish’s post-grant practice group, recently spoke with Bloomberg Law about the push by generic drug makers to preserve IPR proceedings as the Supreme Court prepares to hear oral arguments in Arthrex, the case that could decide their future.
Fish & Richardson Named Law360 2020 IP Practice Group of the Year
Fish & Richardson has been named a 2020 IP Practice Group of the Year by Law360 for its high-profile wins in federal courts across the United States, at the Federal Circuit, at the International Trade Commission (ITC), and before the Patent Trial and Appeal Board (PTAB). Fish was one of only six firms nationwide singled out by Law360 for this prestigious award. This is the seventh time the firm has received this honor.
Legal Alert: USPTO Requests Comments on Discretion to Institute Trials Before the PTAB
The USPTO announced in the Federal Register that it is seeking comments on considerations for instituting trials under the America Invents Act (AIA). Specifically, the USPTO is considering the codification of its current policies and procedures, or modification thereof, regarding its discretion to institute AIA trials.